Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis

Journal of Korean Medical Science

Volumn 29, Issue 9, 2014, Pages 1205-1211

  Kang, Ji Hyoun ^a   Park, Dong Jin ^a   Lee, Jeong Won ^a   Lee, Kyung Eun ^a   Wen, Lihui ^a   Kim, Tae Jong ^a   Park, Yong Wook ^a   Lee, Shin Seok ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Ankylosing; Arthritis; Rheumatoid; Spondylitis; Survival; TNF inhibitor

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; SEX DIFFERENCE; SPONDYLITIS, ANKYLOSING; TERTIARY CARE CENTER; TREATMENT REFUSAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR; SEX FACTORS; SPONDYLITIS, ANKYLOSING; TERTIARY CARE CENTERS; TREATMENT REFUSAL; TUMOR NECROSIS FACTORS;

EID: 84929942531     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.9.1205     Document Type: Article

References (34)

1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
2. Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 2004; 63 Suppl 2: ii13-7.
3. Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009; 122: 114-20.
4. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49: 563-70.
5. Hyrich KL, Deighton C, Watson KD; BSRBR Control Centre Consortium, Symmons DP, Lunt M; British Society for Rheumatology Biologics Register. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford) 2009; 48: 1323-7.
6. Hyrich KL, Watson KD, Lunt M, Symmons DP; British Society for Rheumatology Biologics Register (BSRBR). Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 2011;50: 117-23.
7. Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, Askling J; for the ARTIS Study group. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 2013;Nov 27. Epub
8. Simard JF, Neovius M, Askling J; ARTIS Study Group. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors:drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum 2012; 64: 3502-10.
9. Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res 2010; 10: 1362-9.
10. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnicalhle E, Wassenberg S, Antoni C, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005; 64: 1274-9.
11. Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor a inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013; 72: 1149-55.
12. Ornbjerg LM, Ostergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Ringsdal VS, Graudal N, et al. Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2013; 72: 57-63.
13. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010; 69: 2002-8.
14. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
15. Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, Montoro M, Descalzo Má, Carmona L; BIOBADASER 2.0 Study Group. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 2012; 71: 382-5.
16. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006; 8: R72.
17. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012; 71: 1134-42.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
19. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
20. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-83.
21. Busquets N, Tomero E, Descalzo MA, Ponce A, Ortiz-Santamaria V, Suris X, Carmona L, Gomez-Reino JJ. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology (Oxford) 2011; 50: 1999-2004.
22. Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, Kvien TK. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008; 59: 234-40.
23. Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 2011; 38: 1273-81.
24. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009; 1173: 837-46.
25. Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746-52.
26. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72: 1947-55.
27. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011; 70: 284-8.
28. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6.
29. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
30. Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, Dougados M. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006; 33: 2433-8.
31. Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011; 13: R94.
32. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
33. Glintborg B, Ostergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, Rifbjerg-Madsen S, Lorenzen T, Hetland ML. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382-90.
34. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49: 563-70.